t
On 18 November 2026, Convatec Group PLC published a trading update for the ten months ended 31 October 2026, reporting year-to-date organic revenue growth excluding InnovaMatrix of 6.6% and reported growth of 4.8%. The company upgraded its full-year 2026 Group organic revenue growth guidance (excluding InnovaMatrix) to 6.25–7.0%, up from the previous target of 5.5–6.5%. Convatec maintained its expectation for an adjusted operating profit margin of at least 23% and confirmed its $200 million share buyback remains on track for completion in FY26.
| Date | 18 Nov 2026 |
| Time | 07:00:02 |
| Category | Trading updates |
| ID | 5762D |

Trading update for the ten months ended 31 October 2026 18 November 2026
Growth accelerating in the second half
Key points
Accelerating organic revenue growth; increased FY26 guidance for CC and IC
FY26 Group guidance and medium-term financial targets
Jonny Mason, Chief Executive Officer, commented:
“Revenue growth has accelerated in the second half, as we expected. We saw notable strength in Infusion Care, where improved execution enabled us to meet rising demand, ahead of new capacity coming online in 2027. Overall, we continued to gain share in all categories, underpinned by new product launches.
“We are making good progress executing our Accelerate strategy, the next exciting chapter of Convatec’s story. We are investing to accelerate growth, supporting our new product launches which are winning share with healthcare professionals and users. We are improving execution and are positioned to deliver sustainable 6-8% revenue growth and double-digit annual EPS growth, supporting more people around the world with innovative, trusted medical solutions for chronic conditions.”
Other FY26 guidance
Foreign exchange and macroeconomic environment
Launches, innovation and pipeline
Conference call details
Jonny Mason, Chief Executive Officer, and Fiona Ryder, Chief Financial Officer, will host a conference call for analysts and investors to discuss the trading update at 8:30am (UK time) on 18 November 2026. To access the live webcast, please register here.
To ask questions and join by conference call, please register here to receive dial-in details.
Contacts
|
Analysts & Investors |
David Philips Vice President, Head of Investor Relations |
+44 (0) 7909 324994 |
|
|
|
|
|
|
Delene Cole |
|
|
|
Investor Relations Manager |
|
|
|
|
|
|
Media |
FGS Global |
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com.
All product and programme names are trademarks of Convatec and its subsidiaries, including: InnovaMatrix®, ConvaFoam™, ConvaNiox™, Aquacel®, Aquacel™ ConvaFiber™, ConvaVAC™, Esteem Body™, Esenta™, Natura® Body, Flexi-Seal™ Air, Cure™ Aqua, GentleCath Air™ for Women, GentleCath Air™ for Men, GentleCath Air Pocket™, GentleCath Air Set™, Neria™ Guard, Inset™ Guard and me+ programme.
Forward Looking Statements
This document includes certain forward-looking statements with respect to the operations, performance and financial condition of the Group. Forward-looking statements are generally identified by the use of terms such as “believes”, “estimates”, “aims”, “anticipates”, “expects”, “intends”, “plans”, “predicts”, “may”, “will”, “could”, “targets”, “continues”, or their negatives or other similar expressions. These forward-looking statements include all matters that are not historical facts.
Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic and competitive uncertainties and contingencies that are difficult to predict and many of which are outside the Group’s control. As such, no assurance can be given that such future results, including guidance provided by the Group, will be achieved. Forward-looking statements are not guarantees of future performance and such uncertainties and contingencies, including the factors set out in the “Principal Risks” section of the Strategic Report in our Annual Report and Accounts, could cause the actual results of operations, financial condition and liquidity, and the development of the industry in which the Group operates, to differ materially from the position expressed or implied in the forward-looking statements set out in this document. Past performance of the Group cannot be relied on as a guide to future performance.
Forward-looking statements are based only on knowledge and information available to the Group at the date of preparation of this document and speak only as at the date of this document. The Group and its directors, officers, employees, agents, affiliates and advisers expressly disclaim any obligations to update any forward-looking statements (except to the extent required by applicable law or regulation). LEI number - 213800LS272L4FIDOH92
[1] Organic revenue growth is calculated by applying the applicable prior period average exchange rates to the Group's actual performance in the respective period and excluding acquisitions and divestitures.
[2] In the ten months to 31 Oct 2026, non-InnovaMatrix revenue represented over 99.5% of Group revenues.
3 US dollar depreciation YoY drove c.1.1% FX revenue translation benefit YTD.